TY - JOUR T1 - Increased functional connectivity of thalamic subdivisions in patients with Parkinson’s disease JF - medRxiv DO - 10.1101/19002139 SP - 19002139 AU - Conor Owens-Walton AU - David Jakabek AU - Brian D. Power AU - Mark Walterfang AU - Dennis Velakoulis AU - Danielle van Westen AU - Jeffrey C.L. Looi AU - Marnie Shaw AU - Oskar Hansson Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/08/26/19002139.abstract N2 - Parkinson’s disease (PD) affects 2-3% of the population over the age of 65 with loss of dopaminergic neurons in the substantia nigra impacting the functioning of basal ganglia-thalamocortical circuits. The precise role played by the thalamus is unknown, despite its critical role in the functioning of the cerebral cortex, and the abnormal neuronal activity of the structure in PD. Our objective was to more clearly elucidate how functional connectivity and morphology of the thalamus are impacted in PD (n = 32) compared to Controls (n = 20). To investigate functional connectivity of the thalamus we subdivided the structure into two important regions-of-interest, the first with putative connections to the motor cortices and the second with putative connections to prefrontal cortices. We then investigated potential differences in the size and shape of the thalamus in PD, and how morphology and functional connectivity relate to clinical variables. Our data demonstrate that PD is associated with increases in functional connectivity between motor subdivisions of the thalamus and the supplementary motor area, and between prefrontal thalamic subdivisions and nuclei of the basal ganglia, anterior and dorsolateral prefrontal cortices, as well as the anterior and paracingulate gyri. These results suggest that PD is associated with increased functional connectivity of subdivisions of the thalamus which may be indicative alterations to basal ganglia-thalamocortical circuitry.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCO-W would like to acknowledge The Australian National University for their funding support via the University Research Scholarship. Work in DvW and OH's laboratory was supported by the European Research Council, the Swedish Research Council, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Brain Foundation, the Parkinson Foundation of Sweden, the Skåne University Hospital Foundation and the Swedish federal government under the ALF agreement. Funding sources had no role in the conduct of this study, its analysis, interpretation of the data or in the preparation, review or approval of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAnonymized data will be shared by request from any qualified investigator for the sole purpose of replicating procedures and results presented in the article and as long as data transfer is in agreement with EU legislation on the general data protection regulation. Data underlying the results described in our manuscript are available from at Attention: Conor Owens-Walton Academic Unit of Psychiatry & Addiction Medicine Australian National University Medical School Building 4, Level 2, Canberra Hospital Woden, A.C.T. 2605 AUSTRALIA or (conor.owens-walton@anu.edu.au) ER -